Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT02260986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.
Study identification
- NCT ID
- NCT02260986
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 740 participants
Conditions and interventions
Conditions
Interventions
- Dupilumab Drug
- Placebo (for Dupilumab) Drug
- Topical Corticosteroid (TCS) Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2014
- Primary completion
- Jul 31, 2015
- Completion
- Sep 30, 2016
- Last update posted
- Oct 16, 2017
2014 – 2016
United States locations
- U.S. sites
- 50
- U.S. states
- 26
- U.S. cities
- 50
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Hot Springs | Arkansas | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Encinitas | California | — | — |
| Not listed | Oceanside | California | — | — |
| Not listed | Palmdale | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Trumbull | Connecticut | — | — |
| Not listed | Edgewater | Florida | — | — |
| Not listed | Lake Worth | Florida | — | — |
| Not listed | Miami Lakes | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Alpharetta | Georgia | — | — |
| Not listed | Columbus | Georgia | — | — |
| Not listed | Savannah | Georgia | — | — |
| Not listed | West Dundee | Illinois | — | — |
| Not listed | Carmel | Indiana | — | — |
| Not listed | New Albany | Indiana | — | — |
| Not listed | Rockville | Maryland | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Bay City | Michigan | — | — |
| Not listed | Edina | Minnesota | — | — |
| Not listed | Fridley | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Henderson | Nevada | — | — |
| Not listed | Verona | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Corning | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Smithtown | New York | — | — |
| Not listed | Stony Brook | New York | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Norman | Oklahoma | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Lake Oswego | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Exton | Pennsylvania | — | — |
| Not listed | Hazleton | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | West Jordan | Utah | — | — |
| Not listed | South Burlington | Vermont | — | — |
| Not listed | Henrico | Virginia | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
Recently updated Atopic Dermatitis trials
Other public records listing Atopic Dermatitis. Sorted by last update posted; newest first. Not a recommendation.
- NCT04504955: CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness Recruiting
- NCT07783425: A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Not yet recruiting
- NCT06718101: A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis Active, not recruiting
- NCT07643766: A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis Recruiting
- NCT07748169: An Observational Study of Patients With Dermatologic Disease Recruiting
- NCT07746427: Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02260986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2017 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02260986 live on ClinicalTrials.gov.